254 research outputs found

    Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Triggers, Causes, and Outcome (SECRETO): Rationale and design

    Get PDF
    Background: Worldwide, about 1.3 million annual ischaemic strokes (IS) occur in adults aged <50 years. Of these early-onset strokes, up to 50% can be regarded as cryptogenic or associated with conditions with poorly documented causality like patent foramen ovale and coagulopathies. Key hypotheses/aims: (1) Investigate transient triggers and clinical/sub-clinical chronic risk factors associated with cryptogenic IS in the young; (2) use cardiac imaging methods exceeding state-of-the-art to reveal novel sources for embolism; (3) search for covert thrombosis and haemostasis abnormalities; (4) discover new disease pathways using next-generation sequencing and RNA gene expression studies; (5) determine patient prognosis by use of phenotypic and genetic data; and (6) adapt systems medicine approach to investigate complex risk-factor interactions. Design: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO; NCT01934725) is a prospective multi-centre case–control study enrolling patients aged 18–49 years hospitalised due to first-ever imaging-proven IS of undetermined etiology. Patients are examined according to a standardised protocol and followed up for 10 years. Patients are 1:1 age- and sex-matched to stroke-free controls. Key study elements include centralised reading of echocardiography, electrocardiography, and neurovascular imaging, as well as blood samples for genetic, gene-expression, thrombosis and haemostasis and biomarker analysis. We aim to have 600 patient– control pairs enrolled by the end of 2018. Summary: SECRETO is aiming to establish novel mechanisms and prognosis of cryptogenic IS in the young and will provide new directions for therapy development for these patients. First results are anticipated in 2019

    Sarcopenie bij cirrose

    No full text
    Sarcopenie is een vermindering van de spiermassa en -functie en komt vaak voor bij cirrose. Het gaat gepaard met een hogere mortaliteit, vooral bij patiënten die op een transplantatie wachten. Sarcopenie ontstaat als gevolg van meerdere mechanismen, zoals ondervoeding als gevolg van een te lage voedselinname en hypermetabolisme door de leveraandoening, hyperammoniëmie, een afname van de glycogeenreserve in de lever en een wijziging van de circulerende galzuren. Het is makkelijk op te sporen met eenvoudige tools, en er wordt sterk aanbevolen om dat te doen. De technieken die daar het meest voor gebruikt worden, zijn een berekening van de oppervlakte van de skeletspieren ter hoogte van de derde lendenwervel op een coupe van een CT-scan en de meting van de kracht in de pols met behulp van een dynamometer. Het verdient aanbeveling om de voeding van de patiënt aan te passen zodat die voldoende calorieën en eiwitten binnenkrijgt en ’s avonds nog een snack eet, en erop toe te zien dat de patiënt aan aangepaste lichaamsbeweging doet

    Haemopoietic stem cell therapy in cirrhosis: the end of the story?

    No full text
    Chronic liver diseases can lead to cirrhosis, characterised by fibrous septa dissecting the liver parenchyma, affecting both liver function (due to reduced functional mass) and normal intrahepatic venous pressure (due to increased stiffness). Some specific treatments for the underlying causes of the disease exist, such as antiviral treatment for hepatitis B or C virus infection, alcohol abstinence for alcohol-related liver disease, or weight loss strategies for metabolic non-alcoholic fatty liver disease, whereas other causes remain difficult to treat (like genetic disorders or autoimmune problems). Despite existing strategies, some patients still progress towards end-stage liver disease and its associated complications, including ascites, peritonitis, variceal bleeding, or hepatocellular carcinoma. No treatment is available to specifically target fibrosis and cirrhosis, and liver transplantation remains the only curative option. To avoid progression towards end-stage liver disease ultimately requiring a rescue transplantation—which is not devoid of disadvantages (donor organ shortage, challenging surgery, and lifelong immunosuppression)—many researchers are investigating strategies to restore liver functionality. [...

    La NASH: de nouveaux facteurs protecteurs?

    No full text

    The role of the liver in insulin resistance

    No full text

    Patholgie métabolique (insulinorésistance): la stéatohépatite métabolique

    No full text
    La stéatohépatite métabolique: description de cas cliniques, contexte, liens avec l'insulinorésistance, physiopathologie, moyens diagnostiques et traitements
    • …
    corecore